By Fineline Cube 
Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS; NYSE: BMY) China unit. With over 20 years of leadership experience in multinational pharmaceutical companies, Qian brings a proven track record from roles at Roche, Merck, Pfizer, Novartis, and Eli Lilly. At Pfizer and Lilly, he successfully led the market entry of several blockbuster drugs in China and secured listings on the National Reimbursement Drug List (NRDL). Before joining BMS, Qian served as China General Manager and Chief Commercial Officer at LianBio.
Experience and Achievements
Qian’s extensive experience in the pharmaceutical industry includes significant contributions to the market entry of multiple drugs in China. His efforts in securing NRDL listings have enhanced patient access to critical medications. His leadership roles at various multinational pharmaceutical companies have equipped him with the skills and insights necessary to drive BMS’s growth in the Chinese market.
Future Plans
Qian has already been with BMS for 18 months prior to this promotion. Looking ahead, he aims to accelerate the localization of innovative therapies in China. This strategic focus will play a crucial role in expanding BMS’s presence and impact within the Chinese pharmaceutical market.-Fineline Info & Tech